RxDoctor Payments Data

Islam Al-Howaidi, MD

Interventional Cardiology · Pearland, TXNPI 1609021161

Payments from drug & device makers

$2,508in general payments, 2019–2025

Across 122 payments — averaging $20.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$319
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$291
  • Novartis$217
  • Johnson & Johnson$187
  • Merck$151
  • Impulse Dynamics (USA) Inc.$120
  • plus $1K from 30 others

What the payments were for

  • Food & beverage$2,508100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,508 in reported general payments places this provider in the 10th percentile of 686 interventional cardiology providers in Texas.

See all interventional cardiology providers in Texas

Medicare billing

Part B allowed, 2024
$165,768
Medicare patients
536
Services billed
1,889

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban55$57,020
EntrestoSacubitril/Valsartan32$34,686
XareltoRivaroxaban30$24,472
BrilintaTicagrelor34$20,161
Metoprolol Succinate127$1,061
Ranolazine ErRanolazine13$1,043
Atorvastatin Calcium159$977
ClopidogrelClopidogrel Bisulfate120$937
Carvedilol166$879
Amiodarone Hcl18$871
Chlorthalidone52$642
Potassium Chloride47$615
Prasugrel Hcl13$484
Losartan Potassium62$399
Amlodipine Besylate100$385

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$217$34,68632 claims
Johnson & JohnsonXarelto$187$24,47230 claims
AstraZenecaBrilinta$29$20,16134 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 10th percentile of 686 interventional cardiology providers in Texas.

Other interventional cardiology in Pearland

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →